IRAK4-IN-6

Overview

IRAK4-IN-6 is an orally efficacious and selective IRAK4 inhibitor with an IC 50 of 4 nM, and targetes MyD88 L265P mutant diffuse large B cell lymphoma.

Application

Products | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Rheumatoid Arthritis | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Musculoskeletal and Skin Disease | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Arthritis | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Signaling Pathways > IRAK

Product Information

• Catalog No.: HY-130253
• CAS No.: 2454244-02-9
• Molecular Formula: C25H32N10O2
• Molecular Weight: 504.59
• Purity: 99.30%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.08 mg/mL (4.12 mM); Clear solution
• Availability: In-stock

Source

Original product source